Sort
48,018 grants matching “immunotherapy”
Functions and Mechanisms of NF-kB Factors and their Regulators
$1,264,066Ulrich Siebenlist · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
Basic Research Support for the CCR
$1,263,819Robert Wiltrout · Division Of Basic Sciences - Nci · ZIC · FY2011 · CA
Mechanisms Of Immune Mediated Restriction Of HIV Replication In LTNP
$1,263,633Mark Connors · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
DUAL AFFINITY RE-TARGETING (DART) MOLECULES FOR HIV-1 SUPPRESSION
$1,263,565Jeffrey Nordstrom · Macrogenics, Inc. · N01 · FY2018 · AI
Role of mouse microbiome in cancer and inflammation
$1,263,350Giorgio Trinchieri · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Engineering HCC-selective PET agent
$1,262,705Freddy Escorcia · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
CO17 1A/GA733 ANTIGEN IN COLORECTAL CANCER THERAPY
$1,262,549Wistar Institute · P01 · FY2000 · CA
Validation of Serum Neurofilament Light Chain as a Prognostic and Monitoring Biomarker in Multiple Sclerosis
$1,262,170Peter A Calabresi · Johns Hopkins University · U01 · FY2023 · NS
ANTI-PD1 IN COMBINATION WITH AN INHIBITOR OF PCSK9 TO INCREASE MHC CLASS I MOLECULE EXPRESSION ON TUMOR CELLS AS IMMUNOTHERAPY FOR NSCLC
$1,261,852Duke University · · FY2021 · Defense Health Agency
Immunotherapy for Malignant Mesothelioma, Lung Cancer and Thymic Malignancies
$1,261,829Raffit Hassan · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
CD74 IMMUNOTHERAPY OF SYSTEMIC LUPUS ERYTHEMATOSUS
$1,261,678Immunomedics, Inc. · · FY2013 · Department of the Army
Novel Strategies for Brain Tumor Therapy
$1,260,789University Of Pittsburgh At Pittsburgh · P01 · FY2002 · NS
Clonal expansion: a marker of disease activity in stage 1 T1D
$1,259,153S Alice Long · Benaroya Research Inst At Virginia Mason · R01 · FY2025 · DK
Structure and function of eukaryotic DNA transposases
$1,257,643Frederick Dyda · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2020 · DK
Human Monoclonal Antibodies and Antibody-Guided Nanoparticles
$1,257,527Dimiter S Dimitrov · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
Leveraging prenatal tolerance to improve AAV/bNAb therapy outcomes in infancy
$1,257,182Mauricio De Aguiar Martins · University Of Florida · U01 · FY2025 · AI
SPORE in Skin Cancer
$1,256,837Wistar Institute · P50 · FY2001 · CA
Amyloid-Beta Oligomer Selective Immunotherapy for Prodromal or Mild Alzheimer Disease
$1,256,516Eric Siemers · Acumen Pharmaceuticals, Inc. · U01 · FY2018 · AG
Amyloid-Beta Oligomer Selective Immunotherapy for Prodromal or Mild
$1,256,516Jeffrey L Ives · Acumen Pharmaceuticals, Inc. · U01 · FY2018 · AG
Functions and Mechanisms of NF-kB Factors and their Regulators
$1,255,030Ulrich Siebenlist · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
PEDIATRIC AIDS CLINICAL TRIALS GROUP
$1,254,565St. Jude Children'S Research Hospital · U01 · FY2001 · AI
Radiation-induced molecular targets
$1,254,004Norman Coleman · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Mechanistic investigation of therapies for Down Syndrome Regression Disorder
$1,253,643Joaquin M. Espinosa · University Of Colorado Denver · R33 · FY2024 · HD
The Boston Lung Cancer Survival Cohort
$1,253,492David C Christiani · Harvard School Of Public Health · U01 · FY2022 · CA
Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapies
$1,253,006Amanda G Paulovich · Fred Hutchinson Cancer Center · U01 · FY2022 · CA